Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uros Milenkovic

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Nature Reviews. Urology|October 28, 2018
The mechanisms and potential of stem cell therapy for penile fibrosisUros Milenkovic, Maarten Albersen, Fabio Castiglione
Translational Andrology and Urology|April 8, 2020
Evolving therapies for Peyronie's disease: how can we work towards new drugs?Uros Milenkovic, Jolien Duponselle, Trinity J Bivalacqua, et al.
Sexual Medicine Reviews|April 10, 2019
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's DiseaseUros Milenkovic, Marcus M Ilg, Selim Cellek, et al.
Current Opinion in Urology|January 3, 2019
Organ-sparing surgical and nonsurgical modalities in primary penile cancer treatmentYannic Raskin, Joren Vanthoor, Uros Milenkovic, et al.
Sexual Medicine Reviews|January 3, 2017
Stem Cells in Male Sexual Dysfunction: Are We Getting Somewhere?Mohammad Ayodhia Soebadi, Uros Milenkovic, Emmanuel Weyne, et al.
Translational Andrology and Urology|April 8, 2020
The good, bad, and the ugly of regenerative therapies for erectile dysfunctionJeffrey D Campbell, Uros Milenkovic, Mustafa Faruk Usta, et al.
European Urology|September 22, 2018
Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the LiteratureGiorgio Ivan Russo, Uros Milenkovic, Wayne Hellstrom, et al.
BJU International|December 12, 2018
Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocationUros Milenkovic, Marcus M Ilg, Carola Zuccato, et al.
Scandinavian Journal of Urology|September 14, 2020
Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinomaEduard Roussel, Annelies Verbiest, Uros Milenkovic, et al.
European Urology|October 23, 2018
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease ModelsMarcus M Ilg, Marta Mateus, William J Stebbeds, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Nature Reviews. Urology|October 28, 2018
The mechanisms and potential of stem cell therapy for penile fibrosisUros Milenkovic, Maarten Albersen, Fabio Castiglione
Translational Andrology and Urology|April 8, 2020
Evolving therapies for Peyronie's disease: how can we work towards new drugs?Uros Milenkovic, Jolien Duponselle, Trinity J Bivalacqua, et al.
Sexual Medicine Reviews|April 10, 2019
Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's DiseaseUros Milenkovic, Marcus M Ilg, Selim Cellek, et al.
Current Opinion in Urology|January 3, 2019
Organ-sparing surgical and nonsurgical modalities in primary penile cancer treatmentYannic Raskin, Joren Vanthoor, Uros Milenkovic, et al.
Sexual Medicine Reviews|January 3, 2017
Stem Cells in Male Sexual Dysfunction: Are We Getting Somewhere?Mohammad Ayodhia Soebadi, Uros Milenkovic, Emmanuel Weyne, et al.
Translational Andrology and Urology|April 8, 2020
The good, bad, and the ugly of regenerative therapies for erectile dysfunctionJeffrey D Campbell, Uros Milenkovic, Mustafa Faruk Usta, et al.
European Urology|September 22, 2018
Clinical Efficacy of Injection and Mechanical Therapy for Peyronie's Disease: A Systematic Review of the LiteratureGiorgio Ivan Russo, Uros Milenkovic, Wayne Hellstrom, et al.
BJU International|December 12, 2018
Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocationUros Milenkovic, Marcus M Ilg, Carola Zuccato, et al.
Scandinavian Journal of Urology|September 14, 2020
Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinomaEduard Roussel, Annelies Verbiest, Uros Milenkovic, et al.
European Urology|October 23, 2018
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease ModelsMarcus M Ilg, Marta Mateus, William J Stebbeds, et al.
Pageof 3